Hybrid artificial liver support system for treatment of severe liver failure
- PMID: 15682488
- PMCID: PMC4250604
- DOI: 10.3748/wjg.v11.i6.890
Hybrid artificial liver support system for treatment of severe liver failure
Abstract
Aim: To construct a novel hybrid artificial liver support system (HALSS) and to evaluate its efficacy in patients with severe liver failure.
Methods: Hepatocytes were isolated from suckling pig by the modified Seglen's method. Isolated hepatocytes were cultured in a spinner flask for 24 h to form spheroids before use and the functions of spheroids were detected. HALSS consisted of a plasma separator, a hemo-adsorba and a bioreactor with hepatocytes spheroids in its extra-fiber space. HALSS was applied to 10 patients with severe liver failure. The general condition and the biochemical indexes of the patients were studied just before and after the treatment.
Results: The number of cells per liver was about 2-4 x 10(10) (mean, 3.1+/-1.5 x 10(10)). The cell viabilities were more than 95%. After 24 h of spheroid culture, most hepatocytes formed spheroids. The levels of albumin and urea in the medium of spheroid culture were higher than those in supernatant of petri dish culture (P = 0.0015 and 0.0001, respectively). The capacity of albumin production and urea synthesis remained stable for more than one wk and declined rapidly after two weeks in vitro. In HALSS group, the duration of HALSS treatment was 6-10 h each time. All patients tolerated the treatment well without any fatal adverse reaction. After HALSS treatment, the general condition, psychic state, encephalopathy and hepatic function of the patients were improved. The survival rate of the HALSS group, Plasmapheresis group and control group was 30% (3/10), 20% (2/10) and 0% (0/10), respectively (P = 0.024). Two weeks after treatment, Tbil and ALT decreased and the PTA level elevated in HALSS group and pasmapheresis group (P value: 0.015 vs 0.020, 0.009 vs 0.012 and 0.032 vs 0.041, respectively). But there was no significant change of blood albumin concentration before and after treatment in HALSS group and Plasmapheresis group.
Conclusion: The HALSS established by us is effective in supporting liver function of patients with severe liver failure.
Figures




Similar articles
-
Development of a hybrid artificial liver using polyurethane foam/hepatocyte spheroid culture in a preclinical pig experiment.Int J Artif Organs. 2002 Jan;25(1):51-60. doi: 10.1177/039139880202500109. Int J Artif Organs. 2002. PMID: 11853072
-
Efficacy of a larger version of the hybrid artificial liver support system using a polyurethane foam/spheroid packed-bed module in a warm ischemic liver failure pig model for preclinical experiments.Cell Transplant. 2003;12(2):101-7. doi: 10.3727/000000003108746687. Cell Transplant. 2003. PMID: 12797371
-
Liver regeneration using a hybrid artificial liver support system.Artif Organs. 2004 Jan;28(1):53-7. doi: 10.1111/j.1525-1594.2004.07326.x. Artif Organs. 2004. PMID: 14720289
-
Review of a flat membrane bioreactor as a bioartificial liver.Ann Transplant. 2001;6(3):40-6. Ann Transplant. 2001. PMID: 11899896 Review.
-
Liver support technology--an update.Xenotransplantation. 2006 Sep;13(5):380-9. doi: 10.1111/j.1399-3089.2006.00323.x. Xenotransplantation. 2006. PMID: 16925661 Review.
Cited by
-
Functional evaluation of a new bioartificial liver system in vitro and in vitro.World J Gastroenterol. 2006 Feb 28;12(8):1312-6. doi: 10.3748/wjg.v12.i8.1857. World J Gastroenterol. 2006. PMID: 16534893 Free PMC article.
-
Present and Future Developments in Hepatic Tissue Engineering for Liver Support Systems : State of the art and future developments of hepatic cell culture techniques for the use in liver support systems.Cytotechnology. 2006 Mar;50(1-3):163-79. doi: 10.1007/s10616-006-6336-4. Epub 2006 Jun 23. Cytotechnology. 2006. PMID: 19003077 Free PMC article.
-
Evaluation of G3BP1 in the prognosis of acute and acute-on-chronic liver failure after the treatment of artificial liver support system.World J Hepatol. 2024 Feb 27;16(2):251-263. doi: 10.4254/wjh.v16.i2.251. World J Hepatol. 2024. PMID: 38495274 Free PMC article.
-
Systematic review: extracorporeal bio-artificial liver-support system for liver failure.Hepatol Int. 2012 Oct;6(4):670-83. doi: 10.1007/s12072-012-9352-9. Epub 2012 Mar 28. Hepatol Int. 2012. PMID: 26201519
-
Artificial liver support system in treatment of liver failure after acute poisoning.World J Emerg Med. 2011;2(4):283-6. doi: 10.5847/wjem.j.1920-8642.2011.04.007. World J Emerg Med. 2011. PMID: 25215024 Free PMC article.
References
-
- Jauregui HO, Chowdhury NR, Chowdhury JR. Use of mammalian liver cells for artificial liver support. Cell Transplant. 1996;5:353–367. - PubMed
-
- Shaw BW. Auxiliary liver transplantation for acute liver failure. Liver Transpl Surg. 1995;1:194–200. - PubMed
-
- Everhart JE, Lombardero M, Detre KM, Zetterman RK, Wiesner RH, Lake JR, Hoofnagle JH. Increased waiting time for liver transplantation results in higher mortality. Transplantation. 1997;64:1300–1306. - PubMed
-
- Court FG, Wemyss-Holden SA, Dennison AR, Maddern GJ. Bioartificial liver support devices: historical perspectives. ANZ J Surg. 2003;73:739–748. - PubMed
-
- Steczko J, Ash SR, Blake DE, Carr DJ, Bosley RH. Cytokines and endotoxin removal by sorbents and its application in push-pull sorbent-based pheresis: the BioLogic-DTPF System. Artif Organs. 1999;23:310–318. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources